Skip to content

AI for Detection of Brain Aneurysm: Low-cost Opportunistic Screening

AI for Detection of Brain Aneurysm: Low-cost Opportunistic Screening

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07123818
Acronym
AIDALOS-III
Enrollment
10
Registered
2025-08-14
Start date
2025-10-24
Completion date
2030-12-31
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Aneurysm

Keywords

Aneurysm, Intracranial, UIA, Unruptured

Brief summary

The goal of this clinical trial is to verify the opportunistic screening potential of the AI software for detection of brain unruptured intracranial aneurysms (UIA) on routinely performed brain NECT scans in a prospective setting in the Belgian population. The main question the study aims to answer is: Does the AI algorithm has potential to be used as clinical screening potential for detection of brain UIA on brain NECT scans? The performance and the clinical use of the AI algorithm will be measured based on the number of UIA detected by the AI software compared to the number of UIA confirmed by review of a radiologist compared to the number of UIA already known by review of the electronic patient file/additional diagnostic research. Participants will be followed-up following Standard-of-Care (SoC). In addition, participants will be requested to complete a questionnaire (the EQ-5D-5L questionnaire). Furthermore, patient outcomes, complications/death related to the possible (un)ruptured brain aneurysm will be assessed 5 years after study enrolment.

Interventions

AI software that will verify brain NECT scans on the presence of unruptured intracranial aneurysms (UIA). Brain NECT scans will be send to the AI software, after approval of the subject, which will detect possible unruptured intracranial aneurysms (UIA). NECT scans on which a possibe UIA has been detected will be transferred to a platform on which involved radiologist can verify the AI result(s).

Sponsors

Robovision BV
CollaboratorINDUSTRY
Universitair Ziekenhuis Brussel
CollaboratorOTHER
General Hospital Groeninge
CollaboratorOTHER
Ziekenhuis Oost-Limburg
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Intervention model description

Prospective multicentric interventional study design

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* the subject of the NECT scan must be an adult patient (Age ≥ 18 years old); * the NECT scan must be a NECT scan from the brain; * the NECT scan must contain the entire brain * the patient should have at least one of the following risk factors for developing a brain aneurysm * patient is female * patient has a family history of brain aneurysms * patient is 40 years or older * patient has or is treated for a high blood pressure * patient actively smokes cigarettes at time of inclusion * a first informed consent form must be signed before brain NECT scans can be transferred to Robovision * a second signed written informed consent must be obtained before follow-up data will be gathered, if applicable.

Exclusion criteria

\- There are no specific

Design outcomes

Primary

MeasureTime frame
Verify the opportunistic screening potential of the AI software for detection of brain UIA on routinely performed brain NECT scans in a prospective settingan average of 1 month after subject enrolment

Secondary

MeasureTime frameDescription
Verify the percentage of patients that underwent treatment(s) of the UIA after detection of the possible UIA by the AI software, confirmation of possible UIA by the radiologist, and definitive diagnosis of the UIA, by review of the EPD.Through study completion, an average of 5 years.
Measure the health-related quality of life of patients by completion of the EQ-5D-5L questionnaire.From start patient recruitment until 1 month after last patient signed ICF. Questionnaire to be completed 1 months after signing ICF.
Verify patients' complications by review of the EPD after 5 years5 years after patient enrolment.Patient outcomes measured 5 years after end of enrolment (Q4 2030) including whether or not the patient received complications related to the (non-)treated brain aneurysm, died, and/or whether the aneurysm has ruptured. Complications of ruptured brain aneurysms and subsequent subarachnoid hemorraghe can include, but are not limited to, cerebral vasospasm, hydrocephalus, hyponatremia, seizures, stroke, (permanent) brain damage, coma, and/or death.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026